Search

Boehringer Ingelheim and King’s College London join forces to progress new therapeutic concepts in major depressive disorder and schizophrenia

Nintedanib Study: Systemic Sclerosis & Lung Fibrosis | Boehringer Ingelheim US

Boehringer Ingelheim today announced that the first patient was enrolled in the SENSCIS™ (Safety and Efficacy of Nintedanib in SystemicSClerosIS) study.

Transforming the Treatment of Lung Fibrosis through Lung Repair & Regeneration

FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) for Asthma | BI US

FDA approval of SPIRIVA RESPIMAT for maintenance treatment of asthma in patients 12 and older marks a new class of treatment with once-daily prescriptions.

Beyond the Stigma: Living with Schizophrenia

Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program

Research Beyond Borders

OFEV® (nintedanib) Now Available in the United States

How Simulation is Changing the Game in Biotherapeutic Drug Development

Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia

Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies

Ridgefield Research and Innovation

Ridgefield, CT, USA is Boehringer Ingelheim's 3rd largest research sit, where scientists are tackling some of the most difficult challenges in healthcare.

Swine

Generalized pustular psoriasis (GPP): Unmet needs, the reality of living with the condition, and future management

Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD

Top-line Phase II Data for treatment of MASH

Boehringer Ingelheim and Zealand Pharma announced top-line Phase II data for treatment of metabolic dysfuntion-associated steatohepatitis (MASH).

CIA Reporting Requirements

New GPP Consensus Statement Released

National Psoriasis Foundation Releases Consensus Statement on Management of Generalized Pustular Psoriasis (GPP)

Boehringer Ingelheim announces InPedILD PhaseIII trial results

FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype

Corporate Compliance Program

Our E&C Program conforms with the principles and recommendations published in guides from various Federal agencies and industry related organizations

Boehringer Ingelheim Announces U.S. Country Managing Director Jean-Michel Boers Appointed to PhRMA Board of Directors

Boehringer Ingelheim Cares Product Donations Program

Discovery Research Global Post-Doc Program

AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds

Results for Jardiance® (empaglifozin) | BI US

Read more about JARDIANCE, a significant reduction of risk for cardiovascular death or hospitalization for heart failure.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers